BR0107983A - Uso de pramipexol para o tratamento de enfermidades decorrentes de vìcios - Google Patents

Uso de pramipexol para o tratamento de enfermidades decorrentes de vìcios

Info

Publication number
BR0107983A
BR0107983A BR0107983-2A BR0107983A BR0107983A BR 0107983 A BR0107983 A BR 0107983A BR 0107983 A BR0107983 A BR 0107983A BR 0107983 A BR0107983 A BR 0107983A
Authority
BR
Brazil
Prior art keywords
treatment
disorders
pramipexole
addiction
addictive
Prior art date
Application number
BR0107983-2A
Other languages
English (en)
Inventor
Robert C Marshall
Philip F Von Voigtlander
Erik H F Wong
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22676121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0107983(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR0107983A publication Critical patent/BR0107983A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"USO DE PRAMIPEXOL PARA O TRATAMENTO DE ENFERMIDADES DECORRENTES DE VìCIOS". Este pedido de patente descreve o tratamento de enfermidades decorrentes de vícios, enfermidades decorrentes do uso de substâncias psicoativas, enfermidades de intoxicação, enfermidades de inalação, vício de álcool, vício de tabaco e/ou vício de nicotina, que compreende a administração de uma dose não-tóxica terapeuticamente eficaz de pramipexol e derivados e/ou seus sais farmaceuticamente aceitáveis a um paciente.
BR0107983-2A 2000-02-23 2001-02-14 Uso de pramipexol para o tratamento de enfermidades decorrentes de vìcios BR0107983A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18424200P 2000-02-23 2000-02-23
PCT/US2001/001232 WO2001062249A1 (en) 2000-02-23 2001-02-14 Use of pramipexole for the treatment of addictive disorders

Publications (1)

Publication Number Publication Date
BR0107983A true BR0107983A (pt) 2003-01-28

Family

ID=22676121

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107983-2A BR0107983A (pt) 2000-02-23 2001-02-14 Uso de pramipexol para o tratamento de enfermidades decorrentes de vìcios

Country Status (24)

Country Link
US (1) US6410579B2 (pt)
EP (1) EP1257271B1 (pt)
JP (1) JP2003523387A (pt)
KR (1) KR20030016230A (pt)
CN (1) CN1396826A (pt)
AR (1) AR027945A1 (pt)
AT (1) ATE326967T1 (pt)
AU (1) AU781358B2 (pt)
BR (1) BR0107983A (pt)
CA (1) CA2397874A1 (pt)
CO (1) CO5261586A1 (pt)
DE (1) DE60119896T2 (pt)
DK (1) DK1257271T3 (pt)
ES (1) ES2263586T3 (pt)
HK (1) HK1053058A1 (pt)
MX (1) MXPA02008184A (pt)
MY (1) MY127739A (pt)
NZ (1) NZ520974A (pt)
PE (1) PE20011074A1 (pt)
PT (1) PT1257271E (pt)
SI (1) SI1257271T1 (pt)
TW (1) TWI250016B (pt)
WO (1) WO2001062249A1 (pt)
ZA (1) ZA200206119B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
ES2432527T3 (es) 2001-12-11 2013-12-04 University Of Virginia Patent Foundation Uso de pramipexol para tratar la esclerosis lateral amiotrófica
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
PA8578501A1 (es) * 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
RU2252790C1 (ru) * 2004-01-12 2005-05-27 Семенов Сергей Петрович Способ первичной психопрофилактики наркомании среди учащихся 13-15 лет
RU2252789C1 (ru) * 2004-01-12 2005-05-27 Семенов Сергей Петрович Способ первичной психопрофилактики наркомании среди студентов высших учебных заведений
CA2554616A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
CN101022788B (zh) * 2004-08-13 2010-11-10 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
UA93608C2 (ru) * 2004-08-13 2011-02-25 Берингер Ингельхайм Интернациональ Гмбх композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
EP1988875A2 (en) * 2006-02-10 2008-11-12 Boehringer Ingelheim International GmbH Modified release formulation
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (de) 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク. キラル精製置換ベンゾチアゾールジアミンの合成
EP2203448B1 (de) * 2007-09-21 2011-06-22 Sanofi-Aventis Phenothiazin-derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
DE102012108398B4 (de) 2012-09-10 2014-05-22 Schott Ag Kochfeld, Blende, Geräteeinhausung sowie Kamin- oder Ofensichtscheibe mit einem Hologramm und Verfahren zu dessen bzw. deren Herstellung, sowie Verwendung eines Substrats, auf welchem ein Phasenhologramm aufgebracht ist
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
PL3019167T3 (pl) 2013-07-12 2021-06-14 Knopp Biosciences Llc Leczenie podwyższonych poziomów eozynofili i/lub bazofili
DK3033081T3 (da) 2013-08-13 2021-05-31 Knopp Biosciences Llc Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3843227A1 (de) 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
DE3930282A1 (de) * 1989-09-11 1991-03-21 Boehringer Ingelheim Kg Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit
DE3933738A1 (de) 1989-10-10 1991-04-11 Boehringer Ingelheim Kg Neue verwendung von 2-aminothiazol-derivaten (tsh)
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DE4241013A1 (de) 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
US5650420A (en) 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6001861A (en) 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
CA2384840A1 (en) * 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for cocaine craving

Also Published As

Publication number Publication date
WO2001062249A1 (en) 2001-08-30
NZ520974A (en) 2004-04-30
JP2003523387A (ja) 2003-08-05
AR027945A1 (es) 2003-04-16
EP1257271B1 (en) 2006-05-24
AU781358B2 (en) 2005-05-19
PT1257271E (pt) 2006-09-29
AU3445401A (en) 2001-09-03
DE60119896T2 (de) 2006-11-09
PE20011074A1 (es) 2001-10-04
ES2263586T3 (es) 2006-12-16
CO5261586A1 (es) 2003-03-31
DE60119896D1 (de) 2006-06-29
KR20030016230A (ko) 2003-02-26
MY127739A (en) 2006-12-29
ATE326967T1 (de) 2006-06-15
EP1257271A1 (en) 2002-11-20
CA2397874A1 (en) 2001-08-30
MXPA02008184A (es) 2002-11-29
SI1257271T1 (sl) 2006-10-31
TWI250016B (en) 2006-03-01
ZA200206119B (en) 2003-10-31
CN1396826A (zh) 2003-02-12
US6410579B2 (en) 2002-06-25
DK1257271T3 (da) 2006-08-21
HK1053058A1 (zh) 2003-10-10
US20010041727A1 (en) 2001-11-15

Similar Documents

Publication Publication Date Title
BR0107983A (pt) Uso de pramipexol para o tratamento de enfermidades decorrentes de vìcios
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
SE0102276D0 (sv) Device and method for the administration of a medicament
BR0112395A (pt) Derivados de benzotiazol
DE60128258D1 (de) Indanylderivate zur Behandlung von Atemwegserkrankungen
BR0307050A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, sal farmaceuticamente aceitável, e, uso de um composto ou sal
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
ATE308317T1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
BR0309670A (pt) Compostos derivados dicetohidrazina e drogas contendo os compostos como o ingrediente ativo
BR0210075A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou distúrbios da debilitação intelectual e de fadiga de vÈo, cessamento de fumar, dependência de nicotina, dores, e para a colite ulcerativa
ES2153906T3 (es) Uso de incienso para el tratamiento de la enfermedad de alzheimer.
AR039408A1 (es) Composicion farmaceutica en polvo seco para terapia por inhalacion y uso para fabricacion de un medicamento
PT1069900E (pt) Novos tratamentos para disturbios nervosos
NO20023486L (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
EP1228758A4 (en) PROHYLACTIC AND THERAPEUTIC AGENTS FOR INFLAMMABLE COLON DISEASES
BR0311747A (pt) Composição farmacêutica, forma de dose simples ou de múltiplas doses da composição, kit, e, método para tratar doença
BR0309114A (pt) Uso de carboidratos derivados particulados em composições farmacêuticas em pó seco, composição farmacêutica em pó seco para terapia de inalação, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, e, embalagem de medicamento
AP2002002624A0 (en) Use of a combination of compounds in a dry powder inhaler.
PL2253312T3 (pl) Zastosowanie osmolitów uzyskiwanych z bakterii ekstremofilnych do wytwarzania wziewnych środków leczniczych do profilaktyki i leczenia chorób płucnych i sercowo-naczyniowych oraz urządzenie do inhalacji zawierające osmolity jako składnik czynny
BR0112939A (pt) Compostos para o tratamento de distúrbios de dependência
BR0211358A (pt) Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
BR0009327A (pt) Composição farmacêutica para a terapia de sintomas do trato urinário inferior
BR0015024A (pt) Aplicação de carbinóis substituìdos por 2-imidazolila para a preparação de um medicamento para o tratamento ou profilaxia de doenças provocadas por estados isquêmicos
US20170020838A1 (en) Treatment for respiratory disease

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/425, A61P 25/30, A61P 25/334, A61P 25/32, A61P 25/36

Ipc: A61K 31/425 (2009.01), A61P 25/30 (2009.01), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.